Current and emerging treatments for chronic myeloid leukaemia: What have we learnt from the EHA Hybrid Conference 2022?

touchCONGRESS for touchONCOLOGY Listen to Professor Giuseppe Saglio (Italy) cover key data presented at the EHA Hybrid Conference 2022 on the efficacy and safety of current and emerging treatments for CML, and how these may influence clinical practice, as well as expert insights and interpretation from Professor François-Xavier Mahon (France) and Professor Dietger Niederwieser (Germany). Overview Data review with Professor Giuseppe Saglio (00:54) Expert interview with Professor Giuseppe Saglio, Professor François-Xavier Mahon and Professor Dietger Niederwieser (32:50) Interview questions When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice? (35:00) In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs? (41:00) What have we learnt about the clinical considerations for TKI discontinuation?(47:09) Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?(52:26) How should dose modifications be used for TKIs in clinical practice? (57:39) This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Novartis Pharmaceuticals. This activity is provided by touchIME. For further information visit our website: www.touchoncology.com